Limits...
An arched micro-injector (ARCMI) for innocuous subretinal injection.

You YS, Lee CY, Li C, Lee SH, Kim K, Jung H - PLoS ONE (2014)

Bottom Line: ARCMIs were fabricated using three major techniques: reverse drawing lithography, controlled air flow, and electroplating.These specific features were optimized via in-vitro experiments in artificial ocular hemispherical structures and subretinal injection of indocyanine green in porcine eye ex-vivo.We confirmed that the ARCMI was capable of delivering ocular drugs by subretinal injection without unusual subretinal tissue damage, including hemorrhage.

View Article: PubMed Central - PubMed

Affiliation: Nune Eye Hospital, Seoul, Republic of Korea.

ABSTRACT
Several critical ocular diseases that can lead to blindness are due to retinal disorders. Subretinal drug delivery has been developed recently for the treatment of retinal disorders such as hemorrhage because of the specific ocular structure, namely, the blood retinal barrier (BRB). In the present study, we developed an Arched Micro-injector (ARCMI) for subretinal drug delivery with minimal retinal tissue damage. ARCMIs were fabricated using three major techniques: reverse drawing lithography, controlled air flow, and electroplating. In order to achieve minimal retinal tissue damage, ARCMIs were fabricated with specific features such as a 0.15 mm(-1) curvature, 45° tip bevel, 5 mm length, inner diameter of 40 µm, and an outer diameter of 100 µm. These specific features were optimized via in-vitro experiments in artificial ocular hemispherical structures and subretinal injection of indocyanine green in porcine eye ex-vivo. We confirmed that the ARCMI was capable of delivering ocular drugs by subretinal injection without unusual subretinal tissue damage, including hemorrhage.

Show MeSH

Related in: MedlinePlus

A comprehensive process of subretinal injection via the arched micro-injector (ARCMI).(A) The ARCMI penetrates the ocular curves by passing through a trocar cannula, which is used as a surgical aid for protection from ocular tissue damage in ophthalmology. The ARCMI can then be glided up to the target site at the retinal region of posterior segment of the eye. (B) Magnified image of subretinal insertion of indocyanine green via ARCMI. ARCMI slides along the retinal surface to reduce retinal tissue damage. Indocyanine green was injected into the subretinal target site.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4128757&req=5

pone-0104145-g001: A comprehensive process of subretinal injection via the arched micro-injector (ARCMI).(A) The ARCMI penetrates the ocular curves by passing through a trocar cannula, which is used as a surgical aid for protection from ocular tissue damage in ophthalmology. The ARCMI can then be glided up to the target site at the retinal region of posterior segment of the eye. (B) Magnified image of subretinal insertion of indocyanine green via ARCMI. ARCMI slides along the retinal surface to reduce retinal tissue damage. Indocyanine green was injected into the subretinal target site.

Mentions: The comprehensive process of subretinal injection via Arched Micro-injector (ARCMI) is illustrated in Figure 1A. The ARCMI can be inserted into the subretinal space in the posterior segments of the eye by passing through the side of the anterior ocular shell. During insertion of the ARCMI into the eye, a trocar cannula is used as a surgical aid to prevent damage to the ocular shells from the unanticipated force as well as to serve as a surgical passage. The ARCMI was designed to maintain its own curved shape even after penetration through the trocar cannula which was embedded in the anterior scleral near the pars plana. In the present study, ACRMIs were inserted into the subretinal space by gliding up to the target site for injection along the curved retinal surface in the posterior section of the eye as shown in the magnified cross sectional image (Figure 1B). Indocyanine green (Akorn, USA) was chosen as a model drug to easily detect the subretinal delivery and to inspect the retina hole created after subretinal insertion by the ARCMI without impairing the choroidal layer.


An arched micro-injector (ARCMI) for innocuous subretinal injection.

You YS, Lee CY, Li C, Lee SH, Kim K, Jung H - PLoS ONE (2014)

A comprehensive process of subretinal injection via the arched micro-injector (ARCMI).(A) The ARCMI penetrates the ocular curves by passing through a trocar cannula, which is used as a surgical aid for protection from ocular tissue damage in ophthalmology. The ARCMI can then be glided up to the target site at the retinal region of posterior segment of the eye. (B) Magnified image of subretinal insertion of indocyanine green via ARCMI. ARCMI slides along the retinal surface to reduce retinal tissue damage. Indocyanine green was injected into the subretinal target site.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4128757&req=5

pone-0104145-g001: A comprehensive process of subretinal injection via the arched micro-injector (ARCMI).(A) The ARCMI penetrates the ocular curves by passing through a trocar cannula, which is used as a surgical aid for protection from ocular tissue damage in ophthalmology. The ARCMI can then be glided up to the target site at the retinal region of posterior segment of the eye. (B) Magnified image of subretinal insertion of indocyanine green via ARCMI. ARCMI slides along the retinal surface to reduce retinal tissue damage. Indocyanine green was injected into the subretinal target site.
Mentions: The comprehensive process of subretinal injection via Arched Micro-injector (ARCMI) is illustrated in Figure 1A. The ARCMI can be inserted into the subretinal space in the posterior segments of the eye by passing through the side of the anterior ocular shell. During insertion of the ARCMI into the eye, a trocar cannula is used as a surgical aid to prevent damage to the ocular shells from the unanticipated force as well as to serve as a surgical passage. The ARCMI was designed to maintain its own curved shape even after penetration through the trocar cannula which was embedded in the anterior scleral near the pars plana. In the present study, ACRMIs were inserted into the subretinal space by gliding up to the target site for injection along the curved retinal surface in the posterior section of the eye as shown in the magnified cross sectional image (Figure 1B). Indocyanine green (Akorn, USA) was chosen as a model drug to easily detect the subretinal delivery and to inspect the retina hole created after subretinal insertion by the ARCMI without impairing the choroidal layer.

Bottom Line: ARCMIs were fabricated using three major techniques: reverse drawing lithography, controlled air flow, and electroplating.These specific features were optimized via in-vitro experiments in artificial ocular hemispherical structures and subretinal injection of indocyanine green in porcine eye ex-vivo.We confirmed that the ARCMI was capable of delivering ocular drugs by subretinal injection without unusual subretinal tissue damage, including hemorrhage.

View Article: PubMed Central - PubMed

Affiliation: Nune Eye Hospital, Seoul, Republic of Korea.

ABSTRACT
Several critical ocular diseases that can lead to blindness are due to retinal disorders. Subretinal drug delivery has been developed recently for the treatment of retinal disorders such as hemorrhage because of the specific ocular structure, namely, the blood retinal barrier (BRB). In the present study, we developed an Arched Micro-injector (ARCMI) for subretinal drug delivery with minimal retinal tissue damage. ARCMIs were fabricated using three major techniques: reverse drawing lithography, controlled air flow, and electroplating. In order to achieve minimal retinal tissue damage, ARCMIs were fabricated with specific features such as a 0.15 mm(-1) curvature, 45° tip bevel, 5 mm length, inner diameter of 40 µm, and an outer diameter of 100 µm. These specific features were optimized via in-vitro experiments in artificial ocular hemispherical structures and subretinal injection of indocyanine green in porcine eye ex-vivo. We confirmed that the ARCMI was capable of delivering ocular drugs by subretinal injection without unusual subretinal tissue damage, including hemorrhage.

Show MeSH
Related in: MedlinePlus